Clinical Trial Update: Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy [Phase 2]

View source ↗

Summary

The update reports the completion of a Phase 2 study of abarelix in androgen-independent prostate cancer progressing after agonist therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abarelix (abarelix)

Snippet

Sponsor: PRAECIS Pharmaceuticals Inc. | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED